AML
MCID: LKM061
MIFTS: 81

Leukemia, Acute Myeloid (AML)

Categories: Blood diseases, Cancer diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Leukemia, Acute Myeloid

MalaCards integrated aliases for Leukemia, Acute Myeloid:

Name: Leukemia, Acute Myeloid 58 39
Acute Myeloid Leukemia 39 12 77 54 76 38 30 6 44 15 17
Leukemia, Acute Myelogenous 58 76 13 41
Acute Myelogenous Leukemia 12 77 54 15
Acute Undifferentiated Leukemia 60 56 74
Acute Myeloblastic Leukemia 12 77 76
Leukemia, Acute Myeloid, Susceptibility to 58 6
Leukemia, Myelocytic, Acute 12 74
Acute Myelocytic Leukemia 77 76
Leukemia, Myeloid, Acute 45 41
Aml 58 76
Acute Myeloid Leukaemia with Myelodysplasia-Related Features 60
Acute Myeloid Leukemia, Minimal Differentiation, Fab M0 60
Leukemia, Acute Myeloid, Reduced Survival in, Somatic 58
Acute Myeloid Leukemia with Cebpa Somatic Mutations 60
Acute Myeloid Leukemia with Multilineage Dysplasia 60
Myeloid Leukemia, Acute, M4/m4eo Subtype, Somatic 58
Aml with Myelodysplasia-Related Features 60
Pure Familial Acute Myeloid Leukemia 60
Leukemia, Acute Myeloid, Somatic 58
Aml with Cebpa Somatic Mutations 60
Inherited Acute Myeloid Leukemia 60
Acute Non-Lymphoblastic Leukemia 76
Acute Myeloid Leukemia, Somatic 58
Aml with Multilineage Dysplasia 60
Acute Non-Lymphocytic Leukemia 76
Aml - Acute Myeloid Leukemia 12
Leukemia, Acute Myeloblastic 13
Acute Biphenotypic Leukemia 74
Pure Familial Aml 60
Inherited Aml 60
Familial Aml 60

Characteristics:

Orphanet epidemiological data:

60

OMIM:

58
Inheritance:
autosomal dominant
somatic mutation

Miscellaneous:
evidence of anticipation
mean onset age 57 years, 32 years and 13 years in successive generations
many genes with somatic mutation


HPO:

33
leukemia, acute myeloid:
Inheritance somatic mutation autosomal dominant inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:9119
OMIM 58 601626
KEGG 38 H00003
ICD9CM 36 205.0
MeSH 45 D015470
NCIt 51 C27753 C3171
SNOMED-CT 69 17788007 91861009
ICD10 via Orphanet 35 C92.0 C92.8 C95.0
UMLS via Orphanet 75 C0280141 C0856823 C1292773
SNOMED-CT via HPO 70 124975008 263681008 413443009

Summaries for Leukemia, Acute Myeloid

MedlinePlus : 44 Leukemia is cancer of the white blood cells. White blood cells help your body fight infection. Your blood cells form in your bone marrow. In leukemia, however, the bone marrow produces abnormal white blood cells. These cells crowd out the healthy blood cells, making it hard for blood to do its work. In acute myeloid leukemia (AML), there are too many of a specific type of white blood cell called a myeloblast. AML is the most common type of acute leukemia in adults. This type of cancer usually gets worse quickly if it is not treated. Possible risk factors include smoking, previous chemotherapy treatment, and exposure to radiation. Symptoms of AML include: Fever Shortness of breath Easy bruising or bleeding Bleeding under the skin Weakness or feeling tired Weight loss or loss of appetite Tests that examine the blood and bone marrow diagnose AML. Treatments include chemotherapy, other drugs, radiation therapy, stem cell transplants, and targeted therapy. Targeted therapy uses substances that attack cancer cells without harming normal cells. Once the leukemia is in remission, you need additional treatment to make sure that it does not come back. NIH: National Cancer Institute

MalaCards based summary : Leukemia, Acute Myeloid, also known as acute myeloid leukemia, is related to core binding factor acute myeloid leukemia and leukemia, and has symptoms including angina pectoris, edema and chest pain. An important gene associated with Leukemia, Acute Myeloid is CEBPA (CCAAT Enhancer Binding Protein Alpha), and among its related pathways/superpathways are Acute myeloid leukemia and Transcriptional misregulation in cancer. The drugs Folotyn and Ixempra have been mentioned in the context of this disorder. Affiliated tissues include Blood and Blood, and related phenotypes are acute myeloid leukemia and Reduced mammosphere formation

Disease Ontology : 12 A myeloid leukemia that is characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells.

NIH Rare Diseases : 54 Acute myeloid leukemia (AML) is a cancer that affects the blood and bone marrow. Conditions are generally called "acute" when they develop quickly and have an aggressive course. The signs and symptoms of AML vary but may include easy bruising; bone pain or tenderness; fatigue; fever; frequent nosebleeds; bleeding from the gums; shortness of breath; and/or weightloss. AML is one of the most common types of leukemia among adults and is rarely diagnosed in people under age 40. There are many potential causes of AML such as certain blood disorders, inheritedsyndromes, environmental exposures, and drug exposures; however, most people who develop AML have no identifiable risk factor. Treatment may include a combination of chemotherapy, radiation therapy, bone marrow transplant and/or other drug therapy.

UniProtKB/Swiss-Prot : 76 Leukemia, acute myelogenous: A subtype of acute leukemia, a cancer of the white blood cells. AML is a malignant disease of bone marrow characterized by maturational arrest of hematopoietic precursors at an early stage of development. Clonal expansion of myeloid blasts occurs in bone marrow, blood, and other tissue. Myelogenous leukemias develop from changes in cells that normally produce neutrophils, basophils, eosinophils and monocytes.

Wikipedia : 77 Acute myeloblastic leukemia is a form of myeloid leukemia affecting... more...

Description from OMIM: 601626

Related Diseases for Leukemia, Acute Myeloid

Diseases in the Myeloid Leukemia family:

Leukemia, Acute Myeloid Leukemia, Chronic Myeloid
Subacute Myeloid Leukemia Acute Myeloid Leukemia with T(9;11)(p22;q23)
Acute Myeloid Leukemia with T(6;9)(p23;q34)

Diseases related to Leukemia, Acute Myeloid via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 732)
# Related Disease Score Top Affiliating Genes
1 core binding factor acute myeloid leukemia 34.2 CEBPA FLT3 JAK2 KIT KRAS NRAS
2 leukemia 34.1 CEBPA CSF3R ETV6 FLT3 JAK2 KIT
3 acute myeloblastic leukemia with maturation 34.0 FLT3 KIT NPM1
4 cytogenetically normal acute myeloid leukemia 33.9 CEBPA FLT3 NPM1
5 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 33.7 ETV6 FLT3 KIT RUNX1
6 acute erythroid leukemia 33.6 CEBPA GATA2 JAK2 PICALM
7 acute leukemia 33.5 CEBPA ETV6 FLT3 JAK2 KIT MLLT10
8 acute myeloblastic leukemia without maturation 33.2 FLT3 NPM1
9 acute myeloid leukemia with t(8;21)(q22;q22) translocation 33.2 CEBPA FLT3 KIT RUNX1
10 myeloid leukemia 33.0 CEBPA CSF3R DNMT3A ETV6 FLT3 GATA2
11 lymphoid leukemia 31.6 ETV6 FLT3 JAK2
12 myeloid sarcoma 31.6 FLT3 KIT NPM1
13 acute promyelocytic leukemia 31.5 CEBPA CSF3R FLT3 NPM1 NRAS RUNX1
14 myelodysplastic syndrome 31.5 CEBPA CSF3R DNMT3A ETV6 FLT3 GATA2
15 acute t cell leukemia 31.3 LPP MLLT10 NUP214
16 chronic myelomonocytic leukemia 31.2 CSF3R DNMT3A ETV6 FLT3 JAK2 KIT
17 leukemia, acute lymphoblastic 31.1 ETV6 FLT3 PICALM RUNX1
18 precursor t-cell acute lymphoblastic leukemia 31.1 ETV6 FLT3 MLLT10 NUP214 PICALM
19 leukemia, chronic myeloid 31.1 CSF3R ETV6 FLT3 GATA2 JAK2 KIT
20 myeloma, multiple 31.0 JAK2 KIT KRAS NRAS
21 bone marrow cancer 30.9 CSF3R ETV6 FLT3 JAK2 KIT RUNX1
22 juvenile myelomonocytic leukemia 30.9 DNMT3A FLT3 JAK2 KRAS NRAS RUNX1
23 neutrophilia, hereditary 30.9 CSF3R FLT3 JAK2
24 aplastic anemia 30.9 CSF3R FLT3 GATA2 NRAS TERT
25 myelodysplastic myeloproliferative cancer 30.9 CSF3R JAK2 NRAS
26 atypical chronic myeloid leukemia 30.8 CSF3R JAK2 RUNX1
27 aleukemic leukemia cutis 30.8 FLT3 NPM1 RUNX1
28 8p11 myeloproliferative syndrome 30.8 FLT3 KIT RUNX1
29 subacute myeloid leukemia 30.7 FLT3 JAK2
30 familial acute myeloid leukemia with mutated cebpa 12.7
31 therapy related acute myeloid leukemia and myelodysplastic syndrome 12.4
32 cebpa-associated familial acute myeloid leukemia 12.4
33 aml with myelodysplasia-related features 12.1
34 megakaryocytic leukemia 11.9
35 acute monoblastic leukemia 11.9
36 acute myeloid leukemia with inv3(p21;q26.2) or t(3;3)(p21;q26.2) 11.5
37 acute myeloid leukemia with minimal differentiation 11.5
38 myelodysplastic syndrome with excess blasts 11.5
39 platelet disorder, familial, with associated myeloid malignancy 11.4
40 acute non lymphoblastic leukemia 11.4
41 shwachman-diamond syndrome 2 11.3
42 myeloproliferative/lymphoproliferative neoplasms, familial 11.3
43 erythroleukemia, familial 11.3
44 acute myeloid leukemia with t(8;16)(p11;p13) translocation 11.3
45 acute myeloid leukemia with t(9;11)(p22;q23) 11.3
46 acute myeloid leukemia with t(6;9)(p23;q34) 11.3
47 acute myeloid leukemia with npm1 somatic mutations 11.3
48 acute myeloid leukemia and myelodysplastic syndromes related to topoisomerase type 2 inhibitor 11.3
49 ataxia-pancytopenia syndrome 11.3
50 anemia, sideroblastic, 1 11.3

Graphical network of the top 20 diseases related to Leukemia, Acute Myeloid:



Diseases related to Leukemia, Acute Myeloid

Symptoms & Phenotypes for Leukemia, Acute Myeloid

Human phenotypes related to Leukemia, Acute Myeloid:

33
# Description HPO Frequency HPO Source Accession
1 acute myeloid leukemia 33 HP:0004808

Symptoms via clinical synopsis from OMIM:

58
Hematology:
acute myelogenous leukemia (aml)

Clinical features from OMIM:

601626

UMLS symptoms related to Leukemia, Acute Myeloid:


angina pectoris, edema, chest pain

GenomeRNAi Phenotypes related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.23 CEBPA CSF3R DNMT3A ETV6 KRAS NRAS

MGI Mouse Phenotypes related to Leukemia, Acute Myeloid:

47 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.48 CEBPA CSF3R DNMT3A ETV6 FLT3 GATA2
2 hematopoietic system MP:0005397 10.34 CEBPA CSF3R DNMT3A ETV6 FLT3 GATA2
3 growth/size/body region MP:0005378 10.32 CEBPA DNMT3A ETV6 FLT3 GATA2 JAK2
4 homeostasis/metabolism MP:0005376 10.32 CEBPA DNMT3A ETV6 FLT3 GATA2 JAK2
5 mortality/aging MP:0010768 10.32 CEBPA CHIC2 CSF3R DNMT3A ETV6 FLT3
6 embryo MP:0005380 10.31 DNMT3A ETV6 GATA2 JAK2 KIT KRAS
7 immune system MP:0005387 10.27 CEBPA CSF3R DNMT3A ETV6 FLT3 JAK2
8 endocrine/exocrine gland MP:0005379 10.26 CEBPA DNMT3A ETV6 FLT3 GATA2 JAK2
9 cardiovascular system MP:0005385 10.16 CEBPA ETV6 GATA2 KIT KRAS NPM1
10 integument MP:0010771 10.13 CEBPA CHIC2 ETV6 JAK2 KIT KRAS
11 liver/biliary system MP:0005370 10.06 CEBPA GATA2 JAK2 KIT KRAS NPM1
12 neoplasm MP:0002006 10.02 CEBPA ETV6 FLT3 JAK2 KIT KRAS
13 no phenotypic analysis MP:0003012 9.86 CEBPA ETV6 FLT3 KIT KRAS NRAS
14 normal MP:0002873 9.81 CEBPA ETV6 GATA2 JAK2 KIT KRAS
15 pigmentation MP:0001186 9.35 CHIC2 KIT KRAS NRAS PICALM
16 reproductive system MP:0005389 9.23 CEBPA DNMT3A GATA2 JAK2 KIT KRAS

Drugs & Therapeutics for Leukemia, Acute Myeloid

FDA approved drugs:

# Drug Name Active Ingredient(s) 19 Company Approval Date
1
Folotyn 19 50 PRALATREXATE Allos Therapeutics September 2009
2
Ixempra 19 50 IXABEPILONE Bristol-Myers Squibb October 2007
3
Leukine 19 SARGRAMOSTIM Immunex on November 24, 1995/ November 1996
4
Mylotarg 19 50 GEMTUZUMAB OZOGAMICIN Wyeth May 2000
5
Arcapta 19 INDACATEROL MALEATE Novartis July 2011

Drugs for Leukemia, Acute Myeloid (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 726)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cytarabine Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 147-94-4, 65-46-3 6253
2
Idarubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58957-92-9 42890
3
Vidarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 24356-66-9 21704 32326
4
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 75607-67-9, 21679-14-1 30751
5
Decitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2353-33-5 451668
6
Daunorubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 20830-81-3 30323
7
Mitoxantrone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 65271-80-9 4212
8
Etoposide Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 33419-42-0 36462
9
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
10
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 135968-09-1
11
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
12
Sargramostim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 123774-72-1, 83869-56-1
13
tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1401-55-4
14
Topotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 119413-54-6, 123948-87-8 60700
15
Amsacrine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 51264-14-3 2179
16
Aldesleukin Approved Phase 4,Phase 3,Phase 2,Phase 1 110942-02-4, 85898-30-2
17
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
18
Lenalidomide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 191732-72-6 216326
19
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
20
Thiotepa Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 52-24-4 5453
21
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 62-31-7, 51-61-6 681
22
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 51-45-6 774
23
Micafungin Approved, Investigational Phase 4,Phase 2 235114-32-6 477468 3081921
24
Posaconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 171228-49-2 147912
25
Nicotine Approved Phase 4,Not Applicable 54-11-5 89594 942
26
Bupropion Approved Phase 4,Phase 2 34841-39-9, 34911-55-2 444
27
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 2 1406-16-2
28
Vitamin D3 Approved, Nutraceutical Phase 4,Phase 2 67-97-0 5280795 6221
29
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7440-70-2 271
30
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 5283731 6433735
31
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 2 50-14-6 5280793
32 Molgramostim Investigational Phase 4,Phase 3 99283-10-0
33
Aclarubicin Investigational Phase 4,Phase 2,Phase 1,Not Applicable 57576-44-0 451415
34 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
35 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
36 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
37 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
38 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
39 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
40 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
41 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
42 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Etoposide phosphate Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
46 Antineoplastic Agents, Phytogenic Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
47 Interferon-alpha Phase 4,Phase 2,Phase 1,Not Applicable
48 interferons Phase 4,Phase 2,Phase 1,Not Applicable
49 Cyclosporins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
50 Gemtuzumab Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 2681)
# Name Status NCT ID Phase Drugs
1 Idarubicin at Different Dosages as Induction Therapy for Newly Diagnosed Acute Myeloid Leukaemia Unknown status NCT02277847 Phase 4 Idarubicin(8mg/m2) and cytosine arabinoside;Idarubicin(10mg/m2), cytosine arabinoside
2 AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine Chemotherapy Unknown status NCT02024308 Phase 4 Fludarabine;Cytarabine
3 Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation Unknown status NCT01806116 Phase 4 decitabine
4 3 Anthracyclines, 2 Types of Consolidation With Different ARA-C Doses and Maintenance in Adult Acute Myeloid Leukemia Unknown status NCT01587430 Phase 4 high dose ARA-C;standard dose ARA-C
5 Efficacy of G-CSF-Priming in Elderly AML Patients Unknown status NCT00199147 Phase 4 Cytarabine;Etoposide;Idarubicin;G-CSF;Fludarabine
6 Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT Unknown status NCT02027064 Phase 4 Interferon-alpha
7 Different Doses of Anti-thymocyte Globin to Treat Child Severe Aplastic Anemia Unknown status NCT01997372 Phase 4 ATG
8 Treatment Protocol of Child SAA With the Injection of Mesenchymal Stem Cells(Umbilical Cord Derived) Unknown status NCT02218437 Phase 4 MSC+ATG
9 LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML) Completed NCT01041040 Phase 4 gemtuzumab
10 Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years Completed NCT00464217 Phase 4 ARA-C;Idarubicin;Leucomax
11 Fludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed NCT00488709 Phase 4 Topotecan;Fludarabine;Cytarabine
12 Respiratory Viral Infections During Acute Myeloid Leukemia (AML)Chemotherapy Related Aplasia Completed NCT01819792 Phase 4
13 Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of Acute Myeloid Leukemia With t(8;21) Active, not recruiting NCT03026842 Phase 4 Decitabine;Daunorubicin, Cytarabine;Mitoxantrone, Cytarabine;Aclacinomycin, Cytarabine
14 SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia Completed NCT00487448 Phase 4 Fludarabine;Cytarabine;G-CSF;Idarubicin
15 AML2003 - Standard-Therapy vs Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 Years Completed NCT00180102 Phase 4 Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone
16 Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia Completed NCT01347996 Phase 4 histamine dihydrochloride and IL-2
17 Early Tapering of Immunosuppressive Agents to Immunomodulation to Improve Survival of AML Patients Recruiting NCT03150134 Phase 4 Cyclosporine;routine reduction of immunosuppressive drugs(cyclosporine)
18 Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Completed NCT01200355 Phase 4 micafungin;posaconazole
19 Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML Recruiting NCT02926586 Phase 4 Fludarabine;Cytarabine
20 AML96 - Risk-Adapted and Randomized Postremission-Therapy for Adult Acute Myeloid Leukemia Patients Completed NCT00180115 Phase 4 Cytarabine Dosage
21 LENA-LMA-5:Lenalidomide in Acute Myeloid Leukemia (AML) Terminated NCT01198054 Phase 4 Lenalidomide
22 Therapy of Acute Myeloid Leukemia in Patients Over the Age of 60 : DA Versus Mitoxantrone With Intermittent AraC Completed NCT00180167 Phase 4 randomization between two established Chemotherapies
23 Efficacy and Safety of rhTPO for the Treatment of Thrombocytopenia After Chemotherapy in AML Patients Completed NCT02267993 Phase 4 recombinant human thrombopoietin
24 Evaluating QTc, PK, Safety of Gemtuzumab Ozogamicin (GO) in Patients With CD33+ R/R AML Not yet recruiting NCT03727750 Phase 4 Gemtuzumab Ozogamicin
25 Study Evaluating the Effect of Corticosteroids on Mylotarg® Infusion-Related Adverse Events in Patients With Leukemia Completed NCT00304447 Phase 4 Mylotarg
26 Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections Recruiting NCT02805946 Phase 4 posaconazole
27 King's Invasive Aspergillosis Study II Active, not recruiting NCT02875743 Phase 4 Posaconazole
28 Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115) Completed NCT00686543 Phase 4 Posaconazole
29 Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia Recruiting NCT02618109 Phase 4
30 A Rollover Study to Provide Continued Treatment With Eltrombopag Recruiting NCT01957176 Phase 4 ELT
31 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor Recruiting NCT02933333 Phase 4
32 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
33 A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT Enrolling by invitation NCT03176849 Phase 4
34 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
35 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
36 the Effects and Safety of Idarubicin-strengthened Pretreatment Program and Conventional Busulfan Cyclophosphamide Pretreatment Program on High-risk Acute Myeloid Leukemia Patient Unknown status NCT01766375 Phase 3 Cyclosporin A,mycophenolate mofetil,Methotrexate
37 HLA-mismatched Microtransplantation for High Risk Acute Myeloid Leukemia Unknown status NCT01484171 Phase 3 idarubicin
38 Reduced Intensity Conditioning Transplantation Versus Standard of Care in Acute Myeloid Leukemia Unknown status NCT00342316 Phase 3
39 Recombinant Human Thrombopoietin (rhTPO) in Management of Chemotherapy-induced Thrombocytopenia in Acute Myelocytic Leukemia Unknown status NCT02244658 Phase 3 rhTPO
40 Safety and Efficacy Study of Microtransplantation to Treat Elderly Acute Myeloid Leukemia Unknown status NCT02171117 Phase 3
41 Therapeutic Effect and Safety Study of Decitabine in Elderly Acute Myeloid Leukemia Patients Unknown status NCT01633099 Phase 3 Decitabine
42 Idarubicin Versus High Dose Daunorubicin in Acute Myelogenous Leukemia (AML) Unknown status NCT01145846 Phase 3 Cytarabine plus Daunorubicin [Arm II (AD regimen)]
43 Treatment of Adults Aged Up to 60 Years With De Novo Acute Myeloblastic Leukaemia,Secondary AML, or RAEB-T Unknown status NCT00209833 Phase 2, Phase 3 Cytarabine;Idarubicin;Etoposide;Fludarabine;G-CSF;Daunorubicine
44 Sorafenib for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3-ITD Positive AML Unknown status NCT02474290 Phase 2, Phase 3 Sorafenib
45 Randomised Prospective Comparison of the NMA Allograft and the Traditional Allograft in Acute Myeloid Leukaemia Unknown status NCT00224614 Phase 3
46 Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study Unknown status NCT00715637 Phase 3 Daunorubicin and Cytarabine;Amonafide and Cytarabine
47 Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia Unknown status NCT00002658 Phase 3 amsacrine;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin
48 Combination Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia Unknown status NCT00003602 Phase 3 cytarabine;etoposide;idarubicin;mitoxantrone hydrochloride
49 Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and Adolescents Unknown status NCT00111345 Phase 2, Phase 3 Anthracyclines;liposomal daunorubicin;2-CDA;AI
50 Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia Unknown status NCT00006045 Phase 3 cytarabine;etoposide;mitoxantrone hydrochloride

Search NIH Clinical Center for Leukemia, Acute Myeloid

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Leukemia, Acute Myeloid cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: leukemia, myeloid, acute

Genetic Tests for Leukemia, Acute Myeloid

Genetic tests related to Leukemia, Acute Myeloid:

# Genetic test Affiliating Genes
1 Acute Myeloid Leukemia 30 CBFB CEBPA CHIC2 DNMT3A ETV6 FLT3 GATA2 JAK2 KIT KRAS LPP MLF1 MLLT10 NPM1 NSD1 NUP214 PICALM RUNX1 SH3GL1 TERT

Anatomical Context for Leukemia, Acute Myeloid

MalaCards organs/tissues related to Leukemia, Acute Myeloid:

42
Myeloid, Bone, Bone Marrow, T Cells, Nk Cells, Testes, Breast
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Leukemia, Acute Myeloid:
# Tissue Anatomical CompartmentCell Relevance
1 Blood Hematopoietic Bone Marrow Common Myeloid Progenitor Cells Affected by disease
2 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate

Publications for Leukemia, Acute Myeloid

Articles related to Leukemia, Acute Myeloid:

(show top 50) (show all 8195)
# Title Authors Year
1
Development of pre-engraftment syndrome, but not acute graft-versus-host disease, reduces relapse rate of acute myeloid leukemia after single cord blood transplantation. ( 30771495 )
2019
2
Very rare lineage switch from acute myeloid leukemia to mixed phenotype acute leukemia, B/Myeloid, during chemotherapy with no clonal evolution. ( 30707502 )
2019
3
Sorafenib improves survival of FLT3-mutated acute myeloid leukemia in relapse after allogeneic stem cell transplantation: a report of EBMT acute leukemia Working Party. ( 30792203 )
2019
4
Umbilical cord blood versus unrelated donor transplantation in adults with primary refractory or relapsed acute myeloid leukemia: a report from Eurocord, the Acute Leukemia Working Party and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the EBMT. ( 30979868 )
2019
5
Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). ( 31023346 )
2019
6
Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. ( 30104717 )
2019
7
Haploidentical versus unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: a report on 1578 patients from the Acute Leukemia Working Party of the EBMT. ( 30361416 )
2019
8
Clinical, immunophenotypic, and genomic findings of acute undifferentiated leukemia and comparison to acute myeloid leukemia with minimal differentiation: a study from the bone marrow pathology group. ( 31000771 )
2019
9
Comparing the epidemiology, clinical characteristics and prognostic factors of acute myeloid leukemia with and without acute promyelocytic leukemia. ( 30715157 )
2019
10
Multifocal muscle candidiasis of the legs in a patient with acute myeloid leukemia: A case report. ( 30813175 )
2019
11
Rhino-orbital Mucormycosis presenting as facial cellulitis in a patient with high-risk acute myeloid leukemia in relapse. ( 30686650 )
2019
12
Non-acute promyelocytic leukemia variant, acute myeloid leukemia with translocation (11;17). ( 30899494 )
2019
13
Allogeneic stem cell transplantation using HLA-matched donors for acute myeloid leukemia with deletion 5q or monosomy 5: a study from the Acute Leukemia Working Party of the EBMT. ( 31048355 )
2019
14
Hearing Status in Survivors of Childhood Acute Myeloid Leukemia Treated With Chemotherapy Only: A NOPHO-AML Study. ( 30550508 )
2019
15
Parental age and the risk of childhood acute myeloid leukemia: results from the Childhood Leukemia International Consortium. ( 30776582 )
2019
16
CD82 supports survival of childhood acute myeloid leukemia cells via activation of Wnt/β-catenin signaling pathway. ( 30862962 )
2019
17
Measurable residual disease monitoring using Wilms tumor gene 1 expression in childhood acute myeloid leukemia based on child-specific reference values. ( 30900388 )
2019
18
Construction of prognostic risk prediction model based on high-throughput sequencing expression profile data in childhood acute myeloid leukemia. ( 30954792 )
2019
19
The benefit of chronic graft-versus-host disease in patients with acute myeloid leukemia relapsed after allogeneic stem cell transplantation. ( 30993416 )
2019
20
Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia. ( 30613922 )
2019
21
Predictive Model for Infection Risk in Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Patients Treated With Azacitidine; Azacitidine Infection Risk Model: The Polish Adult Leukemia Group Study. ( 30898482 )
2019
22
Bone marrow mesenchymal stem/stromal cells from risk-stratified acute myeloid leukemia patients are anti-inflammatory in in vivo preclinical models of hematopoietic reconstitution and severe colitis. ( 30237260 )
2019
23
Acute myeloid leukemia with central diabetes insipidus. ( 30709625 )
2019
24
Minimally differentiated acute myeloid leukemia with ring/marker derived from chromosome 7 in a child with Down syndrome. ( 30793109 )
2019
25
Development of acute lymphoblastic leukemia following treatment for acute myeloid leukemia in children with Down syndrome: A case report and retrospective review of Children's Oncology Group acute myeloid leukemia trials. ( 30908863 )
2019
26
Epigenetic Therapy in a Patient With Down Syndrome and Refractory Acute Myeloid Leukemia. ( 29668549 )
2019
27
Disseminated fusariosis with ecthyma gangrenosum-like lesions in a refractory acute myeloid leukemia patient. ( 31049455 )
2019
28
Neutropenic enterocolitis in patients with FLT3 mutated acute myeloid leukemia undergoing induction chemotherapy with midostaurin. ( 30506467 )
2019
29
Shared cell of origin in a patient with Erdheim Chester disease and acute myeloid leukemia. ( 30923101 )
2019
30
Anthracycline-Induced Cardiotoxicity in Acute Myeloid Leukemia Patients Who Undergo Allogeneic Hematopoietic Stem Cell Transplantation. ( 30948329 )
2019
31
Unrelated donor hematopoietic stem cell transplantation for pediatric de novo acute myeloid leukemia with intermediate- or high-risk cytogenetics. ( 30955250 )
2019
32
Impact of treatment-related weight changes from diagnosis to hematopoietic stem-cell transplantation on clinical outcome of acute myeloid leukemia. ( 30963469 )
2019
33
Sorafenib therapy is associated with improved outcomes for FLT3-ITD AML relapsing after allo-HSCT. ( 31009704 )
2019
34
Natural Killer Immunotherapy for Minimal Residual Disease Eradication Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia. ( 31027331 )
2019
35
Expression level of GAS6-mRNA influences the prognosis of acute myeloid leukemia patients with allogeneic hematopoietic stem cell transplantation. ( 31028135 )
2019
36
Correction: Allogeneic hematopoietic stem cell transplantation for relapsed acute myeloid leukemia in ETO positive with reduced-intensity conditioning. ( 31040914 )
2019
37
Autologous hematopoietic stem cell transplantation in acute myeloid leukemia. ( 31054985 )
2019
38
Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome. ( 31089280 )
2019
39
Hematopoietic stem cell transplantation for children with acute myeloid leukemia in second remission: A report from the Australasian Bone Marrow Transplant Recipient Registry and the Australian and New Zealand Children's Haematology Oncology Group. ( 31111633 )
2019
40
Graft γδ TCR Sequencing Identifies Public Clonotypes Associated with Hematopoietic Stem Cell Transplantation Efficacy in Acute Myeloid Leukemia Patients and Unravels Cytomegalovirus Impact on Repertoire Distribution. ( 30710048 )
2019
41
Comparison of Myeloablative Versus Reduced-Intensity Conditioning Regimens for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia: A Cohort Study ( 30717586 )
2019
42
Unmanipulated haploidentical versus HLA-matched sibling allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute myeloid leukemia: a retrospective study on behalf of the ALWP of the EBMT. ( 30718798 )
2019
43
Hematopoietic stem-cell transplantation in children with refractory acute myeloid leukemia. ( 30718800 )
2019
44
Impacts of post-transplantation cyclophosphamide treatment after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. ( 30765830 )
2019
45
Ambulatory Hematopoietic Stem Cell Transplantation in Young Adults with Acute Myeloid Leukemia Treated with Venetoclax and Low Doses of Cytarabine: Report of Two Cases. ( 30835153 )
2019
46
Geriatric nutritional risk index (GNRI) just before allogeneic hematopoietic stem cell transplantation predicts transplant outcomes in patients older than 50 years with acute myeloid leukemia in complete remission. ( 30899981 )
2019
47
Hematopoietic Stem Cell Transplantation From Haploidentical Donors in Aplasia After Cladribine/Cytarabine Chemotherapy for Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome. ( 30905537 )
2019
48
Venetoclax plus decitabine induced complete remission with molecular response in acute myeloid leukemia relapsed after hematopoietic stem cell transplantation. ( 30431666 )
2019
49
Hematopoietic stem cell transplantation for adult patients with isolated NPM1 mutated acute myeloid leukemia in first remission. ( 30456896 )
2019
50
Efficacy and Feasibility of Allogeneic Hematopoietic Stem-Cell Transplantation in the Treatment of Refractory Acute Myeloid Leukemia. ( 30616990 )
2019

Variations for Leukemia, Acute Myeloid

UniProtKB/Swiss-Prot genetic disease variations for Leukemia, Acute Myeloid:

76
# Symbol AA change Variation ID SNP ID
1 CEBPA p.His84Leu VAR_072677 rs28931590
2 JAK2 p.Lys607Asn VAR_032696 rs121912472
3 JAK2 p.Val617Phe VAR_032697 rs77375493
4 SETBP1 p.Gly870Ser VAR_063809 rs267607040
5 SETBP1 p.Ser854Ala VAR_069848
6 SETBP1 p.Gly870Arg VAR_069854
7 SETBP1 p.Ile871Ser VAR_069856

ClinVar genetic disease variations for Leukemia, Acute Myeloid:

6 (show top 50) (show all 853)
# Gene Variation Type Significance SNP ID Assembly Location
1 ETV6 NM_001987.4(ETV6): c.226G> T (p.Glu76Ter) single nucleotide variant Pathogenic rs121434637 GRCh37 Chromosome 12, 11992136: 11992136
2 ETV6 NM_001987.4(ETV6): c.226G> T (p.Glu76Ter) single nucleotide variant Pathogenic rs121434637 GRCh38 Chromosome 12, 11839202: 11839202
3 ETV6 NM_001987.4(ETV6): c.1307_1308insGGG (p.His436delinsGlnGly) insertion Pathogenic rs587776710 GRCh37 Chromosome 12, 12043928: 12043929
4 ETV6 NM_001987.4(ETV6): c.1307_1308insGGG (p.His436delinsGlnGly) insertion Pathogenic rs587776710 GRCh38 Chromosome 12, 11890994: 11890995
5 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
6 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh38 Chromosome 17, 7674221: 7674221
7 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
8 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh38 Chromosome 17, 7674220: 7674220
9 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
10 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh38 Chromosome 17, 7673802: 7673802
11 TP53 NM_000546.5(TP53): c.839G> C (p.Arg280Thr) single nucleotide variant Uncertain significance rs121912660 GRCh37 Chromosome 17, 7577099: 7577099
12 TP53 NM_000546.5(TP53): c.839G> C (p.Arg280Thr) single nucleotide variant Uncertain significance rs121912660 GRCh38 Chromosome 17, 7673781: 7673781
13 KRAS NM_033360.3(KRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic rs112445441 GRCh37 Chromosome 12, 25398281: 25398281
14 KRAS NM_033360.3(KRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic rs112445441 GRCh38 Chromosome 12, 25245347: 25245347
15 KRAS NM_004985.4(KRAS): c.35G> A (p.Gly12Asp) single nucleotide variant Pathogenic rs121913529 GRCh37 Chromosome 12, 25398284: 25398284
16 KRAS NM_004985.4(KRAS): c.35G> A (p.Gly12Asp) single nucleotide variant Pathogenic rs121913529 GRCh38 Chromosome 12, 25245350: 25245350
17 KRAS NM_004985.4(KRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic rs121913529 GRCh37 Chromosome 12, 25398284: 25398284
18 KRAS NM_004985.4(KRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic rs121913529 GRCh38 Chromosome 12, 25245350: 25245350
19 KRAS NM_004985.4(KRAS): c.27_29dupTGG (p.Gly10_Ala11insGly) duplication Pathogenic rs606231202 GRCh38 Chromosome 12, 25245356: 25245358
20 KRAS NM_004985.4(KRAS): c.27_29dupTGG (p.Gly10_Ala11insGly) duplication Pathogenic rs606231202 GRCh37 Chromosome 12, 25398290: 25398292
21 KRAS NM_004985.4(KRAS): c.458A> T (p.Asp153Val) single nucleotide variant Pathogenic rs104894360 GRCh37 Chromosome 12, 25362838: 25362838
22 KRAS NM_004985.4(KRAS): c.458A> T (p.Asp153Val) single nucleotide variant Pathogenic rs104894360 GRCh38 Chromosome 12, 25209904: 25209904
23 HRAS NM_176795.4(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
24 HRAS NM_176795.4(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
25 HRAS NM_005343.3(HRAS): c.437C> T (p.Ala146Val) single nucleotide variant Likely pathogenic rs121917759 GRCh38 Chromosome 11, 533466: 533466
26 HRAS NM_005343.2(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
27 HRAS NM_005343.3(HRAS): c.437C> T (p.Ala146Val) single nucleotide variant Likely pathogenic rs121917759 GRCh37 Chromosome 11, 533466: 533466
28 HRAS NM_005343.2(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh38 Chromosome 11, 534288: 534288
29 HRAS NM_005343.4(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
30 HRAS NM_005343.4(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh38 Chromosome 11, 534286: 534286
31 HRAS NM_005343.3(HRAS): c.436G> A (p.Ala146Thr) single nucleotide variant Pathogenic/Likely pathogenic rs104894231 GRCh37 Chromosome 11, 533467: 533467
32 HRAS NM_005343.3(HRAS): c.436G> A (p.Ala146Thr) single nucleotide variant Pathogenic/Likely pathogenic rs104894231 GRCh38 Chromosome 11, 533467: 533467
33 HRAS NM_005343.2(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
34 HRAS NM_005343.2(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
35 KIT NM_000222.2(KIT): c.2447A> T (p.Asp816Val) single nucleotide variant Uncertain significance rs121913507 GRCh37 Chromosome 4, 55599321: 55599321
36 KIT NM_000222.2(KIT): c.2447A> T (p.Asp816Val) single nucleotide variant Uncertain significance rs121913507 GRCh38 Chromosome 4, 54733155: 54733155
37 KIT NM_000222.2(KIT): c.2446G> T (p.Asp816Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913506 GRCh37 Chromosome 4, 55599320: 55599320
38 KIT NM_000222.2(KIT): c.2446G> T (p.Asp816Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913506 GRCh38 Chromosome 4, 54733154: 54733154
39 NRAS NM_002524.4(NRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121434595 GRCh37 Chromosome 1, 115258745: 115258745
40 NRAS NM_002524.4(NRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121434595 GRCh38 Chromosome 1, 114716124: 114716124
41 NRAS NM_002524.3(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
42 NRAS NM_002524.3(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic rs11554290 GRCh38 Chromosome 1, 114713908: 114713908
43 NRAS NM_002524.3(NRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic rs121434596 GRCh37 Chromosome 1, 115258744: 115258744
44 NRAS NM_002524.3(NRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic rs121434596 GRCh38 Chromosome 1, 114716123: 114716123
45 NPM1 NM_002520.6(NPM1): c.860_863dupTCTG (p.Trp288Cysfs) duplication Pathogenic rs587776806 GRCh38 Chromosome 5, 171410540: 171410543
46 NPM1 NM_002520.6(NPM1): c.860_863dupTCTG (p.Trp288Cysfs) duplication Pathogenic rs587776806 GRCh37 Chromosome 5, 170837544: 170837547
47 NPM1 NM_002520.6(NPM1): c.863_864insCATG (p.Trp288Cysfs) insertion Pathogenic rs1554138188 GRCh38 Chromosome 5, 171410543: 171410544
48 NPM1 NM_002520.6(NPM1): c.863_864insCATG (p.Trp288Cysfs) insertion Pathogenic rs1554138188 GRCh37 Chromosome 5, 170837547: 170837548
49 NPM1 NM_002520.6(NPM1): c.863_864insCGTG (p.Trp288Cysfs) insertion Pathogenic rs1554138188 GRCh38 Chromosome 5, 171410543: 171410544
50 NPM1 NM_002520.6(NPM1): c.863_864insCGTG (p.Trp288Cysfs) insertion Pathogenic rs1554138188 GRCh37 Chromosome 5, 170837547: 170837548

Copy number variations for Leukemia, Acute Myeloid from CNVD:

7 (show top 50) (show all 491)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13336 1 1 124300000 Insertion Acute myeloid leukemia
2 13759 1 1 28000000 Deletion Acute myeloid leukemia
3 14790 1 110122000 110569000 Gain or loss Acute myeloid leukemia
4 17466 1 142902432 245422360 Duplication Acute myeloid leukemia
5 18096 1 143961000 247125000 Gain or loss Acute myeloid leukemia
6 20826 1 154656757 154656845 Amplification Acute myeloid leukemia
7 24589 1 182359000 182787000 Loss Acute myeloid leukemia
8 26098 1 197094625 197094734 Amplification Acute myeloid leukemia
9 26100 1 197094796 197094905 Amplification Acute myeloid leukemia
10 27148 1 204981000 205049000 Gain or loss Acute myeloid leukemia
11 27263 1 206041820 206041907 Amplification Acute myeloid leukemia
12 27859 1 214500000 224100000 Deletion Acute myeloid leukemia
13 28491 1 222606000 222909000 Gain or loss Acute myeloid leukemia
14 29341 1 230606000 230646000 Gain or loss Acute myeloid leukemia
15 32943 1 40683565 40683656 Amplification Acute myeloid leukemia
16 32944 1 40686494 40686582 Amplification Acute myeloid leukemia
17 33084 1 42072000 42456000 Gain or loss Acute myeloid leukemia
18 35033 1 5913000 7696000 Gain or loss Acute myeloid leukemia
19 35608 1 65296705 65296779 Amplification Acute myeloid leukemia
20 35769 1 67074000 69951000 Gain or loss Acute myeloid leukemia
21 36085 1 71305902 71305987 Amplification miR-186 Acute myeloid leukemia
22 38187 10 1 6700000 Insertion IL15RA Acute myeloid leukemia
23 38188 10 1 6700000 Insertion PRKCQ Acute myeloid leukemia
24 38677 10 104186259 104186331 Deletion Acute myeloid leukemia
25 38804 10 105144000 105144148 Deletion Acute myeloid leukemia
26 39144 10 110889374 110889450 Deletion Acute myeloid leukemia
27 39902 10 122017230 122017301 Deletion let-7a-2 Acute myeloid leukemia
28 41668 10 21893278 22027081 Loss MLLT10 Acute myeloid leukemia
29 41990 10 27075530 27189965 Translate SSH3BP1 Acute myeloid leukemia
30 43278 10 46100000 49900000 Copy number GDF10 Acute myeloid leukemia
31 44445 10 57165247 57165335 Deletion Acute myeloid leukemia
32 44874 11 64658609 64658718 Deletion miR-192 Acute myeloid leukemia
33 45369 10 70521000 135283000 Gain Acute myeloid leukemia
34 47681 10 96486000 100815000 Loss Acute myeloid leukemia
35 49592 11 108316750 133951370 Triplication Acute myeloid leukemia
36 50142 11 114500000 121200000 Copy number MLL Acute myeloid leukemia
37 50190 11 115400000 120700000 Insertion DDX6 Acute myeloid leukemia
38 50191 11 115400000 120700000 Insertion ETS1 Acute myeloid leukemia
39 50192 11 115400000 120700000 Insertion FLI1 Acute myeloid leukemia
40 50193 11 115400000 120700000 Insertion MLL Acute myeloid leukemia
41 50261 11 116297361 116448564 Loss Acute myeloid leukemia
42 50346 11 117203762 118563610 Amplification Acute myeloid leukemia
43 50385 11 117603158 117860329 Duplication Acute myeloid leukemia
44 50437 11 117820656 117856311 Gain MLL Acute myeloid leukemia
45 50640 11 118585028 127052111 Deletion Acute myeloid leukemia
46 51468 11 126537000 130235000 Gain Acute myeloid leukemia
47 51512 11 127394408 133951311 Amplification Acute myeloid leukemia
48 52810 11 2016406 2019065 Methylation H19 Acute myeloid leukemia
49 53744 11 32409321 32457081 Mutation WT1 Acute myeloid leukemia
50 54217 11 39671000 39746000 Loss Acute myeloid leukemia

Expression for Leukemia, Acute Myeloid

Search GEO for disease gene expression data for Leukemia, Acute Myeloid.

Pathways for Leukemia, Acute Myeloid

Pathways related to Leukemia, Acute Myeloid according to KEGG:

38
# Name Kegg Source Accession
1 Acute myeloid leukemia hsa05221
2 Transcriptional misregulation in cancer hsa05202

Pathways related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.27 CEBPA CSF3R FLT3 JAK2 KIT KRAS
2
Show member pathways
13.2 CSF3R FLT3 JAK2 KIT KRAS NRAS
3
Show member pathways
12.64 CSF3R FLT3 JAK2 KIT KRAS NRAS
4
Show member pathways
12.63 CEBPA FLT3 KIT KRAS NRAS RUNX1
5 12.35 CEBPA GATA2 JAK2 KIT RUNX1
6
Show member pathways
12.26 CSF3R JAK2 KRAS NRAS
7
Show member pathways
12.16 FLT3 JAK2 KRAS NRAS
8 12.05 CEBPA ETV6 FLT3 RUNX1
9 12 CEBPA CSF3R FLT3 JAK2 KIT KRAS
10 11.93 FLT3 JAK2 KIT NPM1
11
Show member pathways
11.81 JAK2 KRAS NRAS
12 11.77 JAK2 KRAS NRAS
13 11.75 CSF3R FLT3 KIT
14 11.61 CSF3R JAK2 KRAS NRAS
15 11.6 CEBPA KIT NRAS
16 11.5 GATA2 NPM1 TERT
17
Show member pathways
11.48 JAK2 KRAS NRAS
18
Show member pathways
11.38 FLT3 KIT KRAS NRAS
19 11.16 JAK2 KRAS NRAS
20 11.07 FLT3 KIT KRAS NRAS
21 10.84 DNMT3A ETV6 FLT3
22 10.67 KRAS NRAS

GO Terms for Leukemia, Acute Myeloid

Cellular components related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.85 CEBPA DNMT3A GATA2 JAK2 MLLT10 NPM1
2 nucleus GO:0005634 9.8 CEBPA DNMT3A ETV6 FLT3 GATA2 JAK2
3 focal adhesion GO:0005925 9.02 JAK2 KRAS LPP NPM1 NUP214

Biological processes related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.91 FLT3 JAK2 KIT KRAS NPM1
2 negative regulation of transcription by RNA polymerase II GO:0000122 9.91 CEBPA DNMT3A ETV6 GATA2 NSD1 RUNX1
3 negative regulation of gene expression GO:0010629 9.78 GATA2 PICALM RUNX1 TERT
4 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.58 FLT3 JAK2 KIT
5 MAPK cascade GO:0000165 9.55 FLT3 JAK2 KIT KRAS NRAS
6 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.54 FLT3 JAK2 KIT
7 positive regulation of MAP kinase activity GO:0043406 9.5 FLT3 KIT KRAS
8 hematopoietic stem cell proliferation GO:0071425 9.49 ETV6 RUNX1
9 regulation of myeloid cell differentiation GO:0045637 9.46 CSF3R RUNX1
10 cytokine-mediated signaling pathway GO:0019221 9.43 CEBPA CSF3R FLT3 JAK2 KIT KRAS
11 myeloid progenitor cell differentiation GO:0002318 9.26 FLT3 KIT
12 hemopoiesis GO:0030097 9.02 FLT3 GATA2 KIT PICALM RUNX1

Molecular functions related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chromatin binding GO:0003682 9.65 DNMT3A GATA2 MLLT10 NPM1 NSD1
2 protein binding GO:0005515 9.6 CEBPA CHIC2 CSF3R DNMT3A ETV6 FLT3
3 nucleotide binding GO:0000166 9.55 FLT3 JAK2 KIT KRAS NRAS
4 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.43 CEBPA DNMT3A ETV6 GATA2 NSD1 RUNX1

Sources for Leukemia, Acute Myeloid

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....